Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

Vincent Chung, John S. Kovach, Richard S. Ungerleider et al.|Clinical Cancer Research|2016

Cited by 126